CNSP vs. MIRA, GOVX, NRSN, GLYC, IPA, LPTX, CLRB, COCP, ME, and SPRB
Should you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include MIRA Pharmaceuticals (MIRA), GeoVax Labs (GOVX), NeuroSense Therapeutics (NRSN), GlycoMimetics (GLYC), ImmunoPrecise Antibodies (IPA), Leap Therapeutics (LPTX), Cellectar Biosciences (CLRB), Cocrystal Pharma (COCP), 23andMe (ME), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry.
CNS Pharmaceuticals vs.
CNS Pharmaceuticals (NASDAQ:CNSP) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.
CNS Pharmaceuticals received 45 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave MIRA Pharmaceuticals an outperform vote while only 70.59% of users gave CNS Pharmaceuticals an outperform vote.
14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 0.1% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
CNS Pharmaceuticals' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.
CNS Pharmaceuticals has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500.
MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 2 mentions for MIRA Pharmaceuticals and 0 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.00 beat MIRA Pharmaceuticals' score of -0.29 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.
CNS Pharmaceuticals presently has a consensus price target of $25.00, indicating a potential upside of 2,303.85%. MIRA Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,308.17%. Given CNS Pharmaceuticals' higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than MIRA Pharmaceuticals.
Summary
MIRA Pharmaceuticals beats CNS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get CNS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CNS Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CNSP) was last updated on 4/25/2025 by MarketBeat.com Staff
